“…There is poor correlation between patients with thrombosis harboring ACLAs and those harboring LAs, and stronger, but still not concordant, correlation between patients with thrombosis with ACLAs and those with antibodies to B-2-GP-I or antibodies to phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, annexin-V, and phosphatidylcholine. Although there are similarities, there are, at times, clinical, laboratory, and biochemical differences, particularly regarding prevalence, etiology, possible mechanisms of thrombosis, clinical presentations, diagnosis, and at times, management [4,5]. The ACLA-thrombosis antiphospholipid syndrome is much more common than the LA-thrombosis antiphospholipid syndrome, the ratio being approximately 5 to 1 [3,6,7].…”